MUMBAI, Mar 7: Pharma Major Lupin Limited (Lupin) announced today the launch of generic Paxil CR (Paroxetin) Extended Release Tablets USP, 12.5 mg, 25 mg and 37.5 mg having received an approval from the United States Food and Drug Administration (FDA) earlier. Lupin’s Paroxetin Extended Release Tablets USP, 12.5 mg, 25 mg and 37.5 mg are the AB rated generic equivalents of Apotex Technologies, Inc’s Paxil CR Tablets, 12.5 mg, 25 mg and 37.5 mg. It is indicated for the treatment of major depressive disorder, panic disorder, social anxiety disorder and premenstrual dysphoric disorder. Paxil CR Tablets had US sales of USD 126.4 million (IMS MAT December 2016). (UNI)
Follow our WhatsApp channel
